All In Biotech

NDA 209627 · Mayne Pharma

Annovera

Ethinyl Estradiol, Segesterone Acetate · Vaginal · Estrogen

Novel

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 10, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

501

113 Phase 3, 20 recruiting

FAERS reports

383

75 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in females over 35 years of age, and with the number of cigarettes smoked. For this reason, CHC should not be used by females who are over 35 years of age and smoke. [See Contraindications (4) and Warnings and Precautions (5.5) ]. WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. Females over 35 years old who smoke should not use ANNOVERA. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. ( 4 )

What it is approved for

From the label in effect Sep 17, 2026.

ANNOVERA is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use ANNOVERA has not been adequately studied in females with a BMI >29 kg/m 2 . ANNOVERA is a progestin/estrogen CHC indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitation of Usage Not adequately evaluated in females with a body mass index of >29 kg/m 2 ( 1 )

Mechanism: CHCs lower the risk of becoming pregnant primarily by suppressing ovulation.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 10, 2018 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLabelLetterReview
1 products under this application
  • ANNOVERA · ETHINYL ESTRADIOL 0.013MG/24HR; SEGESTERONE ACETATE 0.15MG/24HR · RING, VAGINAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • intermenstrual bleeding44
  • off label use36
  • vaginal haemorrhage36
  • nausea34
  • drug ineffective26
  • headache23
  • vaginal discharge18
  • vomiting17
  • device expulsion15
  • pulmonary embolism13
  • depression12
  • metrorrhagia12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
202057
202186
202287
202338
202430
202552
202632

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Annovera (Segesterone Ac/Ethin Estradiol)

2024 spending

$90K

Beneficiaries

39

40 claims

Per beneficiary

$2,308

$2,250.63 per unit

View as table
YearSpending
2020$57,228
2021$127,234
2022$146,414
2023$110,515
2024$90,025

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,068 on PubMed

Sponsor: Mayne Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.